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Abstract: Objective: The aim of this systematic review was to explore the relationship between coeliac
disease (CD) and headache. The objectives were to establish the prevalence of each entity amongst
the other, to explore the role of gluten free diet (GFD), and to describe the imaging findings in those
affected by headaches associated with CD. Methodology: A systematic computer-based literature
search was conducted on the PubMed database. Information regarding study type, population size,
the age group included, prevalence of CD amongst those with headache and vice versa, imaging
results, the nature of headache, and response to GFD. Results: In total, 40 articles published between
1987 and 2017 qualified for inclusion in this review. The mean pooled prevalence of headache
amongst those with CD was 26% (95% CI 19.5–33.9%) in adult populations and 18.3% (95% CI
10.4–30.2%) in paediatric populations. The headaches are most often migraine-like. In children
with idiopathic headache, the prevalence of CD is 2.4% (95% CI 1.5–3.7%), whereas data for adult
populations is presently unavailable. Brain imaging can be normal, although, cerebral calcifications
on CT, white matter abnormalities on MRI and deranged regional cerebral blood flow on SPECT can
be present. GFD appears to be an effective management for headache in the context of CD, leading to
total resolution of headaches in up to 75% of patients. Conclusions: There is an increased prevalence
of CD amongst idiopathic headache and vice versa. Therefore, patients with headache of unknown
origin should be screened for CD, as such patients may symptomatically benefit from a GFD.
Keywords: gluten sensitivity; coeliac disease; gluten free diet; migraine; headache
1. Introduction
Gluten-related disorders (GRDs) represent a diverse spectrum of clinical entities for which the
ingestion of gluten is a common trigger.
Coeliac disease (CD) is the best-recognised GRD and it is characterized by a small bowel
enteropathy occurring in genetically susceptible individuals whilst exposed to the protein gliadin [1].
Non-coeliac gluten sensitivity (NCGS) is a term that is used by gastroenterologists to describe patients
with primarily gastrointestinal (GI) symptoms that are related to the ingestion of wheat, barley,
and rye, who do not have enteropathy, but do symptomatically benefit from a gluten free diet (GFD) [2]
However, in the context of neurological manifestations, patients might have serological evidence of
gluten sensitivity (GS); usually anti-gliadin IgG and/or IgA (AGA), with or without transglutaminase
(TG) or endomysial antibodies (EMA), but no histological changes on biopsy of the bowel to suggest
CD [3]. Such patients might still benefit neurologically from a strict GFD.
Although the gastrointestinal manifestations of GRDs are themost prevalent, a range of debilitating
neurological manifestations are increasingly being recognised in clinical practice, often preceding or in
the absence of GI symptoms. The most well-known neurological GRDs are cerebellar ataxia [4] and
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peripheral neuropathy [5], however clear links between GS/CD and epilepsy [3], various movement
disorders [6], and headaches [7] have also been described.
The aim of this paper is to systematically review the current literature in order to establish the
relationship between headache and CD.
2. Methods
2.1. Literature Search Strategy
This study is reported in accordance with the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) guidelines [8]. A systematic search was performed on the 29 August
2018 using the PubMed database. For the search, two medical subject headings (MeSH terms) were
used and they were restricted to title/abstract fields. Term A was “coeliac” or “celiac” or “gluten”.
Term B was “headache” or “migraine”. English language was applied as a filter. The reference lists of
included articles were examined in order to identify further relevant articles.
2.2. Inclusion and Exclusion Criteria
Articles to be included in the review were required to meet the following criteria:
1. The study subjects were diagnosed with idiopathic headache and gluten sensitivity or
coeliac disease.
2. The study subjects were human.
3. The study contained original data.
4. The study was available as a full-text, English language article, or contained utilisable information
in an English language abstract.
5. For randomised control trials, a JADAD score [9] of above 3 to ensure good quality and to reduce
any potential bias.
Details of the inclusion process are detailed in the PRISMA chart, Figure 1.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) chart.
2.3. Statistical Analyses
A database was developed using IBM SPSS Statistics (version 23.0 for Mac, IBM. New York,
United States). Data were extracted from each study and included: study type; population size; the age
group included; prevalence of GRD/headache; imaging results; the nature of headache; and, response
to GFD. Frequencies and descriptive statistics were examined for each variable. The outcomes of
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interest were the proportion of patients with CD or GS suffering from headache and the proportion of
patients suffering from idiopathic headache that had CD or GS.
Meta-analysis of the pooled proportions was conducted in R language [10] while using the default
settings of the “meta” package using the “metaprop” function. The meta-analysis of odds ratios
was conducted using the RevMan program [11], as suggested by the Cochrane Collaboration Group.
Heterogeneity between studies was assessed using the I2 statistic. Data were analysed using a random
effects model.
A value of p < 0.05 was considered to be statistically significant.
2.4. Compliance with Ethical Guidelines
This article is based upon previously published studies. The article is in compliance with the
journal’s ethical guidelines.
3. Results
3.1. Selected Studies
The search strategy identified 96 articles. A total of 57 articles were excluded during the eligibility
assessment. After perusing the reference lists of included studies, one additional article meeting our
inclusion criteria was identified, which had not already been discovered in the aforementioned search
strategy. Therefore, in total 40 articles published between 1987 and 2017 qualified for inclusion in this
review, studying a total of 42,388 individuals with either headache or GRD (mean number of patients
per citation 1059.7 ± 4626.5). The characteristics of the included papers are summarised in Table 1.
Figure 1 illustrates the study selection process.
Table 1. Descriptive of studies included in the review.
Parameter Value
Number of papers 40
Population (%)
Adult 18 (45.0)
Children 18 (45.0)
Mixed 4 (10.0)
Type of study
Case report 9 (22.5)
Cohort/Case series 16 (40.0)
Case-controlled study 11 (27.5)
Population-based 2 (5.0)
Survey 2 (5.0)
Gluten-related disorder
Coeliac disease 36 (90.0)
Mixed group: CD/GS 1 (2.5)
Mixed group: NCGS/GS 3 (7.5)
Type of headache reported
Migraine 16 (40.0)
All types 6 (15.0)
Not specified 14 (35.0)
Idiopathic intracranial hypertension–related 2 (5.0)
Encephalopathy syndrome 2 (5.0)
Imaging *
MRI 8 (20.0)
CT 7 (17.5)
SPECT 2 (5.0)
No imaging data 24 (60.0)
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Table 1. Cont.
Parameter Value
Year of publication (%)
Until 2000 5 (12.5)
2000–2009 15 (37.5)
2010–2018 20 (50.0)
* Some citations had data on more than one imaging types.
3.2. Prevalence of Headache in Patients with CD
Only one population based epidemiological study, inclusive of all ages, has been conducted
to date [12]. In this population-based retrospective cohort study that was conducted in Sweden,
Lebwohl et al. reported that among 28,638 patients with CD and 143,126 controls, headache-related
visits occurred in 4.7% and 2.9% of each group, respectively, suggesting a hazard ratio of 1.7 (95% CI
1.6–1.8; p < 0.0001). However, in this study, there was no information provided regarding the criteria
for headache diagnosis used and if diagnosed, its exact type.
Information about prevalence of headache in adults was available through five cohort [13–17] and
four case-controlled studies [18–21]. As shown in Figure 2, the pooled mean prevalence of headache in
adults with CD was 26% (95% CI 19.5–33.9%). The meta-analysis of the four case-controlled studies is
summarized in Figure 3; the odds of having a headache were significantly higher in the CD groups
when compared to controls (OR 2.7, 95% CI 1.7–4.3, p < 0.0001).
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Figure 2. Pooled mean prevalence of headache in adults with coeliac disease.
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Figure 3. Meta-analysis results as illustrated in the forest plot regarding the odds of having headache
in adults with coeliac disease compared to controls.
Information about prevalence of headache in children and adolescents, was available through
five cohort [17,22–25], one case-controlled [26], and one population-based study [27]. As shown in
Figure 4, the pooled mean prevalence of headache in children and adolescents with CD was 18.3%
(95% CI 10.4–30.2%). A cross-sectional, population-based study that was conducted by Assa et al. [27]
investigated the association between CD and various comorbidities, demonstrating that the odds
of suffering from headache were significantly higher in children and adolescents with CD when
compared to controls (OR 2.3, 95% CI 2.1–2.5, p < 0.0001).
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Figure 4. Pooled mean prevalence of headache in children with coeliac disease.
3.3. Prevalence of CD in Patients with Idiopathic Headache
Headache, usually migraine, has been reported as the first manifestation of CD in several case
reports [28–36].
In a case-controlled study, Gabrielli et al. [37] investigated the prevalence of CD amongst 90 adults
with idiopathic migraine when compared to blood donor controls. Of them, 4.4% were found to have
CD against 0.4% of controls (p < 0.05).
Information about prevalence of CD in children with headache was available through two
case-control [38,39] and two cohort studies [26,40]. As demonstrated in Figure 5, the pooled mean
prevalence of CD in children with idiopathic headache is 2.4% (95% CI 1.5–3.7%), which is significantly
higher as compared to the prevalence of CD in the general population in the same age group. Although
in one of these studies the authors conclude that that the prevalence of CD was not higher in patients
with migraine relative to the control group [38], the other three studies concluded that the odds of a
child with headache having CD is significantly higher than in children without headaches, with OR
ranging from 1.7 to 8.3 [26,39,40].
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Figure 5. Pooled mean prevalence of coeliac disease in children with idiopathic headache.
3.4. Imaging Findings
Sixteen papers provided information regarding imaging findings [7,14,22,26,28–31,33–37,41–43].
3.4.1. Computed Tomography (CT)
Although brain CT scans in patients with CD and headache are usually normal, there have
been cases described of migraine-like headaches with occipital [29,30] or parieto-occipital [33,35]
calcifications in both adult and children patients. The two patients with headache and parieto-occipital
calcifications being described in the literature were adults, with no evidence of epilepsy or epileptiform
activity on EEG. By contrast, all three patients with headache and occipital calcifications were children,
of which two also had epilepsy. Cerebral calcifications in the context of CD have been associated
with epilepsy [3], which is most commonly known as “epilepsy and cerebral calcification (CEC)
syndrome”. However, although the available evidence is limited, there are cases with calcifications and
migraine-like headaches in the absence of epilepsy. Therefore, patients who present with idiopathic
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headache in the presence of calcifications in the occipital or parieto-occipital areas of the brain should
be screened for CD.
3.4.2. Magnetic Resonance Imaging (MRI)
MRI findings have been reported in isolated case reports and small case series. In a consecutive
cohort of 33 adult patients with CD who were referred for a neurological opinion, Currie et al. reported
that 12 patients (36%) had white matter abnormalities (WMA) on MRI [14]. When looking specifically
into patients with headache, four out of six (67%) hadWMA onMRI. In children, one out of six patients
with headaches and CD that have been reported to date [22,42,43] was found to have WMA on MRI.
Hadjivassiliou et al. has presented the largest series of patients with CD or GS and WMA on MRI
to date [7]. Among 40 adult patients with symptoms and signs of central nervous system dysfunction,
most of which had cerebellar ataxia, ten patients (four with CD and six with GS) were found to
have WMA. All patients had episodic migraine-like headache. In children with GS the available
evidence is limited, however Alehan et al. reported that WMA were present in one out of four TG
positive patients [41]. Therefore, patients of all ages who present with idiopathic headache and have
non-specific WMA on MRI should be screened for CD and GS.
3.4.3. Single Photon Emission Computed Tomography (SPECT)
Gabrielli et al. conducted a case-controlled study of four adult patients with migraine and newly
diagnosed CD and five control patients with migraine, but no CDwho underwent a brain SPECT study,
which was performed by the administration of 740 MBq of 99mTc hexemethyl-propylene-amineoxime
using a brain-dedicated tomograph [37]. All SPECT studies were performed in the headache free
period. All four patients that were affected by both migraine and CD showed evident abnormalities
in regional cerebral blood flow. In all cases, a circumscribed area of cortical hypoperfusion was
present, whereas there were no interhemispheric asymmetries of cortical regional blood flow in the
five migraine patients without evidence of CD.
3.4.4. Positron Emission Tomography (PET)
Lionetti et al. studied the cerebral perfusion in four children headaches and CD with an
eight-ring whole-body PET scanner using 2-[18F]-fluoro-2-deoxy-D-glucose, without identifying any
abnormalities [26]. This could be because of a selection bias, as the patients that underwent PET had
normal standard cerebral imaging, or it might suggest that cerebral hypoperfusion is not present in
children with headaches and CD.
3.5. Effect of Gluten-Free Diet
The effect of a gluten-free diet (GFD) has been reported in numerous cohort studies [7,15,17,20,24–
26,28,37,40]. In adults, a positive response, defined as a significant reduction in headache frequency,
varies from 51.6% [20] to 100% [7,37] of the patients who embarked on a GFD. In up to 75% of adult
patients [15] with CD, GFD led to the total resolution of headache. In children, the response rates
range between 69.2% [24] and 100% [25,28,40]. In up to 71.3% of paediatric patients [25] with CD,
GFD resulted in headache resolution.
As well as direct clinical improvement, it has been demonstrated that a GFD can normalize
the cortical hypoperfusion abnormalities that are seen in SPECT [37]. Although, WMA and brain
calcifications are not reversible when present, patients on a strict GFD have a lower incidence of
WMA [14].
In a survey of pediatric patients with CD that was conducted by Rashid et al., it was reported
that up to 13% of patients experience headache after accidental gluten ingestion [44]. In a similar
survey of predominantly adults (patients > 16 years old) with CD, Zarkadas et al. found that 23%
of patients experienced a headache when they knowingly consumed gluten [45]. In their study,
Faulkner-Hogg et al. reported that dietary analysis of patients with persistent symptoms, including
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headaches, showed that up to 56% of patient still consume traces of gluten. When such patients
switched to a strict GFD their symptoms improved [46]. Therefore, specialist dietician advice should
always be offered to patients with CD and headaches, and their compliance with the diet should be
routinely checked (i.e., AGA titre monitoring).
3.6. Gluten-Related Intracranial Hypertension
Some case reports describe patients who presented with headache secondary to increased
intracranial pressure and CD. Dotan et al. reported two cases of boys (three and four years old)
who presented with idiopathic intracranial hypertension (IIH). Diagnostic work-up revealed low
serum vitamin A titres and further diagnostic work-up led to a diagnosis of CD [43]. A therapeutic
regimen of vitamin A supplements, GFD, and acetazolamide proved very effective. Rani et al. reported
a single case of a 14-year-old girl with IIH, whose diagnostic work-up revealed CD [42]. Despite
the fact that the patient was overweight (BMI 30) a GFD proved to be beneficial, even before the
patient started to lose weight and without requiring administration of acetazolamide. Although these
data are limited and the evidence is currently weak, the potential link between CD and intracranial
hypertension should be investigated further.
3.7. Gluten–Encephalopathy
Gluten encephalopathy is a term that is used to describe a combination of frequent, often
intractable, headaches, and cognitive complaints (which patients sometimes describe as a “foggy
brain”). Crosato et al. were the first to describe a case of a nine-year-old boy with a history of seizures,
headaches, episodes of drowsiness and cerebral calcification on CT who, because of his very low folate
levels, was eventually diagnosed with CD [29]. Kakoraç et al. reported a case of a 48-year old man
who presented with two episodes of headache, confusion, and seizures and normal MRI, and because
of carnitine deficiency, was eventually diagnosed with CD [34].
3.8. NCGS/GS and Headache
A link between headache and NCGS or GS has been also demonstrated in a smaller number
of studies.
Information about prevalence of GS in children with headache (all reporting migraine), was
available through three case-controlled studies [41,47,48]. As shown in Figure 6, the pooled mean
prevalence of GS in childrenwith idiopathic migraine is 6.2% (95%CI 2.6–14.1%). Figure 7 demonstrates
that the odds of having migraine are higher (trend for statistical significance) in children with CD as
compared to controls (OR 2.8, 95% CI 0.9–8.6, p = 0.06).
 
Figure 6. Pooled mean prevalence of serologically confirmed gluten sensitivity in children with
idiopathic migraine.
Information about the prevalence of headache in patients with NCGS was available through two
studies [49,50]. In a cohort of 486 patients (children and adults), 54% presented with headaches [50].
In a cohort of 78 children with NCGS, 32% presented with headaches, when not on a GFD [49]. It is of
interest that 56% of patients with NCGS, when not on a GFD, have positive AGA. This highlights the
need to test patients for AGA, the only currently available biomarker of GS.
Nutrients 2018, 10, 1445 8 of 11
Figure 7. Meta-analysis results as illustrated in the forest plot regarding the odds of having migraine
in children with coeliac disease compared to controls.
4. Conclusions and Future Directions
This systematic review, highlights the following key points:
1. There is an increased prevalence of headache amongst patients with CD and an increased
prevalence of CD amongst those with idiopathic headache. Such an increased prevalence is
evident in both child and adult populations; however, the figures are higher in the latter.
2. Headaches that are associated with CD are predominantly migraines. However, many studies
that were used in this report tended to report headaches without specifying the exact type
(i.e., tension, cluster, migraine, etc.) making the interpretation of the findings more difficult.
3. CT calcifications and WMA are frequent in patients with headaches that are related to CD,
and therefore patients with such imaging findings in in the context of idiopathic headache require
further testing for CD.
4. GFD is a very effective treatment for headaches associated with CD and should therefore be
offered as soon as possible. This is highly consistent with other neurological GRD, such as the
observation that GFD is associated with a significant reduction of pain in patients with gluten
neuropathy and an improvement of their quality of life [51,52]. Specialist dietary advise should
always be offered, as often patients consume gluten, whilst believe that they are on a strict GFD.
Serological testing (i.e., AGA titre) can help in monitoring compliance with diet.
5. Further studies of the prevalence of GS in patients with idiopathic headache are needed. Currently,
to our knowledge, no such studies in adults exist.
6. Although there is some evidence that brain hypoperfusion and perivascular inflammation might
play a role in the pathogenesis of GS-related headaches more studies on the likely pathogenetic
mechanisms are needed.
7. Serum positivity for TG6 antibodies has been identified as a sensitive measure of neurological
involvement in GS [53,54] Therefore, a study of the prevalence of TG6 antibodies in patients with
headaches that are related to CD and GS should be conducted.
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